Oncology

Articles:
195 Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1709937

194 Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31601-X/fulltext

193 Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32247-X/fulltext

192 Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1701769

191 Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1709684

190 Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1614598

189 Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
http://www.nejm.org/doi/full/10.1056/NEJMoa1706450

188 Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1701717

187 Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1702900

186 Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1704174

185 Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
http://stm.sciencemag.org/content/9/398/eaah5583

184 An immunogenic personal neoantigen vaccine for patients with melanoma.
http://www.nature.com/nature/journal/v547/n7662/full/nature22991.html

183 Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
http://stm.sciencemag.org/content/9/384/eaai8504

182 Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611977

181 Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1613683

180 Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30396-3/fulltext

179 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32616-2/fulltext

178 Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32409-6/fulltext

177 AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy.
http://www.pnas.org/content/114/9/E1688

176 Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607529

175 Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1612674

174 A transistor-like pH nanoprobe for tumour detection and image-guided surgery.
http://www.nature.com/articles/s41551-016-0006

173 Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31594-X/fulltext

172 Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1610497

171 Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607427

170 Dermatologist-level classification of skin cancer with deep neural networks.
http://www.nature.com/nature/journal/v542/n7639/full/nature21056.html

169 Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.
http://www.pnas.org/content/114/4/740.abstract

168 A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
http://stm.sciencemag.org/content/9/372/eaag2611

167 Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.
http://www.nature.com/nm/journal/v23/n1/abs/nm.4232.html

166 Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation.
http://www.nature.com/nm/journal/v23/n1/abs/nm.4252.html

165 Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32517-X/fulltext

164 Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32455-2/fulltext

163 Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32453-9/fulltext

162 T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609279

161 Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611406

160 Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611310

159 TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
http://www.nejm.org/doi/full/10.1056/NEJMoa1605949

158 Palbociclib and Letrozole in Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607303

157 A personalized DC/AML fusion cell vaccine promotes the expansion of leukemia-specific T cells and prolonged remission in patients.
http://stm.sciencemag.org/content/8/368/368ra171.abstract

156 Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609214

Free Images for Presentation: sunipix SUNIPIX